Device companies raised $2.3bn in financing during the second quarter, more than doubling the group’s $1.6bn total from Q1. Once again, debt offerings and late-stage venture financings brought in the most money among the different financing types. (See Exhibit 1.)
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
A Look At The Financing, M&A And Alliance Activity In April–June 2019
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.